Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(6 sites)
Australia
Nucleus Network, Melbourne Georgia
Arensia Exploratory Medicine LLC, Tbilisi Moldova
Clinical Republican Hospital "Timofei Mosneaga", ARENSIA E.M., Chisinau Poland
MICS Centrum Medyczne Torun - MICS - PPDS, Torun Centrum Medyczne Reuma Park, Warsaw Ukraine
"ARENSIA EXPLORATORY MEDICINE" LIMITED LIABILITY COMPANY, Medical Center, Department of Clinical Trials, Kyiv